{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:45:23Z","timestamp":1790941523630,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"vor","delay-in-days":5433,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.1093\/annonc\/mdi047","type":"journal-article","created":{"date-parts":[[2005,1,24]],"date-time":"2005-01-24T19:07:47Z","timestamp":1106593667000},"page":"282-288","source":"Crossref","is-referenced-by-count":92,"title":["A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity"],"prefix":"10.1016","volume":"16","author":[{"given":"M.M.","family":"Borner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bernhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Wernli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Saletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Koeberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Honegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Brauchli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.D.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdi047_bb0010","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdi047_bb0015","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer","volume":"343","author":"Saltz","year":"2000","journal-title":"Irinotecan Study Group. N Engl J Med"},{"key":"10.1093\/annonc\/mdi047_bb0020","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0959-8049(01)00371-9","article-title":"Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin. A randomised crossover trial in advanced colorectal cancer","volume":"38","author":"Borner","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdi047_bb0025","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study","volume":"19","author":"Van Cutsem","year":"2001","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdi047_bb0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0959-8049(01)00415-4","article-title":"Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials","volume":"38","author":"Twelves","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdi047_bb0035","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study","volume":"19","author":"Hoff","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi047_bb0040","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.1996.14.4.1128","article-title":"Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer","volume":"14","author":"Rothenberg","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi047_bb0045","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/oxfordjournals.annonc.a010763","article-title":"Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies","volume":"7","author":"Armand","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdi047_bb0050","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1200\/JCO.2003.08.058","article-title":"Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer","volume":"21","author":"Fuchs","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi047_bb0055","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/annonc\/mdg376","article-title":"Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study dagger","volume":"14","author":"Tewes","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdi047_bb0060","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cncr.11910","article-title":"Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma","volume":"100","author":"Bajetta","year":"2004","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdi047_bb0065","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1023\/A:1008270916325","article-title":"The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK)","volume":"9","author":"Borner","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdi047_bb0070","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1023\/A:1008311918967","article-title":"Quality of life as subjective experience: reframing of perception in patients with colon cancer undergoing radical resection with or without adjuvant chemotherapy. Swiss Group for Clinical Cancer Research (SAKK)","volume":"10","author":"Bernhard","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdi047_bb0075","first-page":"65","article-title":"Patients' estimation of overall treatment burden: why not ask the obvious?","volume":"20","author":"Bernhard","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi047_bb0080","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1054\/bjoc.2001.1785","article-title":"Clinical relevance of single item quality of life indicators in cancer clinical trials","volume":"84","author":"Bernhard","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdi047_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1093\/annonc\/mdi047_bb0090","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1093\/annonc\/mdi047_bb0095","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/annonc\/mdf034","article-title":"Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients","volume":"13","author":"Kohne","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdi047_bb0100","article-title":"Continuous flat-dose capecitabine plus weekly irinotecan: an alternative first-line treatment for metastatic colorectal cancer","volume":"1","author":"Burris","year":"2004","journal-title":"Proceedings of ASCO Gastrointestinal Cancers Symposium"},{"key":"10.1093\/annonc\/mdi047_bb0105","article-title":"Capecitabine and irinotecan as 1st line therapy for patients with metastatic colorectal cancer: Phase II study preliminary results","volume":"22","author":"Gold","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdi047_bb0110","article-title":"A phase I\/II study of CPT-11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer (MCRC)","volume":"21","author":"Kerr","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdi047_bb0115","article-title":"Capecitabine plus irinotecan for chemotherapy-naive patients with metastatic colorectal cancer","volume":"22","author":"Patt","year":"2003","journal-title":"Proceedings of ASCO"},{"key":"10.1093\/annonc\/mdi047_bb0120","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(00)02528-9","article-title":"Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer","volume":"356","author":"Buyse","year":"2000","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdi047_bb0125","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1200\/JCO.2002.08.535","article-title":"Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma","volume":"20","author":"Hobday","year":"2002","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419484044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419484044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/16\/2\/282\/327374\/mdi047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T17:07:40Z","timestamp":1582218460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419484044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["S0923753419484044"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdi047","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2005,2]]}}}